Nagore E, Sevila A, Sanmartin O, Botella-Estrada R, Requena C, Serra-Guillen C, Sanchez-Pedreño P, Guillen C
Department of Dermatology, Instituto Valenciano de Oncología, C/Denia, 20-6a, 46006 Valencia, Spain.
Br J Dermatol. 2003 Oct;149(4):858-61. doi: 10.1046/j.1365-2133.2003.05613.x.
Xeroderma pigmentosum (XP) is an autosomal recessive disease in which patients have a 1000-fold increased risk of developing cutaneous neoplasms. Management of patients with XP is a difficult therapeutic challenge as they usually present with many cutaneous malignancies and continue to form skin tumours at a high rate. We describe a 19-year-old woman with XP who had been previously treated with many different therapeutic approaches. She had an excellent clinical response of her multiple small pigmented basal cell carcinomas and pigmentary changes using imiquimod 5% cream with only minor side-effects.
着色性干皮病（XP）是一种常染色体隐性疾病，患者患皮肤肿瘤的风险增加1000倍。XP患者的治疗是一项艰巨的治疗挑战，因为他们通常会出现许多皮肤恶性肿瘤，并且继续以高发病率形成皮肤肿瘤。我们描述了一名19岁的XP女性患者，她此前接受过多种不同的治疗方法。她使用5%咪喹莫特乳膏治疗多发性小色素性基底细胞癌和色素沉着变化，临床反应良好，且只有轻微副作用。
